GlassScriptPhysician profile
Munaf Abdulateef Alkadimi
NPI 1457882870
$15,604.88
in general payments reported to CMS, 2019-2025
53 companies · $7,050 in 2025
The $7,050 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $249 · 2021: $478 · 2022: $532 · 2023: $1,274 · 2024: $5,898 · 2025: $7,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,229 · Food and Beverage: $5,583 · Education: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,229.00 |
| Food and Beverage | $5,582.57 |
| Education | $409.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,241.82 | 2023-2025 | Tagrisso, Imfinzi, Enhertu |
| Regeneron Pharmaceuticals, INC. | $3,825.77 | 2023-2024 | Libtayo |
| Incyte Corporation | $1,298.98 | 2021-2025 | Zynyz, Monjuvi, Jakafi |
| Astellas Pharma US INC | $471.12 | 2020-2025 | Vyloy, Xospata, Padcev |
| E.R. Squibb & Sons, L.L.C. | $452.48 | 2023-2025 | Opdivo, Reblozyl, Opdualag |
| Janssen Biotech, INC. | $431.79 | 2023-2025 | Rybrevant, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $358.62 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Rigel Pharmaceuticals, INC. | $344.86 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Celgene Corporation | $304.70 | 2024-2025 | Reblozyl |
| Seagen INC. | $289.33 | 2021-2023 | Tukysa |
| Pfizer INC. | $242.77 | 2023-2025 | |
| Abbvie INC. | $222.92 | 2023-2025 | Epkinly |
| Lilly USA, LLC | $197.99 | 2023-2025 | Verzenio, Jaypirca |
| Genzyme Corporation | $183.54 | 2023-2025 | |
| Eisai INC. | $178.79 | 2023-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $169.57 | 2023-2025 | Soliris, Ultomiris |
| Novartis Pharmaceuticals Corporation | $166.21 | 2024-2025 | |
| Glaxosmithkline, LLC. | $145.37 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Myriad Genetic Laboratories, INC. | $133.43 | 2022-2023 | Myrisk |
| Tersera Therapeutics LLC | $129.18 | 2023-2025 | Zoladex, Xermelo |
| Genentech USA, INC. | $127.26 | 2024-2025 | Venclexta, Phesgo |
| Inari Medical, INC. | $127.05 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $124.94 | 2019 | |
| Sobi, INC | $122.10 | 2024-2025 | |
| Kite Pharma, INC. | $107.99 | 2024-2025 | Yescarta |
| Takeda Pharmaceuticals U.S.A., INC. | $98.46 | 2023-2024 | Ninlaro, Alunbrig, Fruzaqla |
| Puma Biotechnology, INC. | $96.90 | 2023-2025 | |
| Gilead Sciences, INC. | $89.23 | 2024-2025 | Trodelvy |
| Fennec Pharmaceuticals, INC. | $76.12 | 2024 | Pedmark |
| Syndax Pharmaceuticals, INC. | $72.19 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.99 | 2024-2025 | |
| Exelixis INC. | $66.34 | 2023-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $62.62 | 2023-2024 | |
| Immunocore Limited | $55.77 | 2023-2024 | Kimmtrak |
| Cti Biopharma Corp. | $46.94 | 2023 | Vonjo |
| Taiho Oncology, INC. | $45.58 | 2025 | |
| Stemline Therapeutics INC. | $36.77 | 2023-2024 | Orserdu |
| Invivyd INC | $33.79 | 2025 | Pemgarda |
| Emd Serono, INC. | $29.87 | 2024 | |
| Array Biopharma INC | $29.70 | 2025 | Lorbrena |
| Beone Medicines USA, INC. | $28.91 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $26.13 | 2024 | Libtayo |
| Adaptive Biotechnologies Corporation | $24.46 | 2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $24.27 | 2024 | |
| Boston Scientific Corporation | $23.95 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Genmab U.S., INC. | $23.35 | 2025 | Tivdak |
| Springworks Therapeutics, INC. | $22.84 | 2025 | Gomekli |
| Daiichi Sankyo INC. | $22.68 | 2025 | Enhertu |
| Sirtex Medical INC | $22.35 | 2025 | Sir-Spheres Microspheres |
| Pharmaessentia USA Corporation | $21.50 | 2024 | Besremi |
| Servier Pharmaceuticals LLC | $19.97 | 2025 | |
| Pharmaand Gmbh | $18.31 | 2025 | Rubraca |
| Tolmar, INC. | $18.31 | 2025 | Rubraca, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munaf Alkadimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.